<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Global Cancer Technology, Inc

    Global Cancer Technology, Inc

    Global Cancer Technology (“GCT”) is an emerging medical technology company with nu...

    Global Cancer Technology (“GCT”) is an emerging...

    Amount Raised:    $82,711.00
    Fundraising Status:    EC
    Filing Type:    CF
    Cumberland Pharmaceuticals Inc.

    Cumberland Pharmaceuticals Inc.

    We are a profitable and growing company focused on the acquisition, development an...

    We are a profitable and growing company focused...

    Filing Type:    PU

    Caresafe, LLC

    Caresafe has developed a self-sanitizing surface coating system that creates conti...

    Caresafe has developed a self-sanitizing surfac...

    Filing Type:    CF
    Mesoblast Limited

    Mesoblast Limited

    Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a world leader in developing allogene...

    Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a ...

    Filing Type:    PU
    Sinovac Biotech, Ltd.

    Sinovac Biotech, Ltd.

    Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on th...

    Sinovac Biotech Ltd. is a China-based biopharma...

    Filing Type:    PU
    Amicus Therapeutics, Inc.

    Amicus Therapeutics, Inc.

    Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology comp...

    Amicus Therapeutics (Nasdaq: FOLD) is a global,...

    Filing Type:    PU
    Jazz Pharmaceuticals plc

    Jazz Pharmaceuticals plc

    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company that...

    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a gl...

    Filing Type:    PU
    BioCurity Pharmaceuticals Inc.

    BioCurity Pharmaceuticals Inc.

    BioCurity is a clinical stage biopharmaceutical company with a mission to material...

    BioCurity is a clinical stage biopharmaceutical...

    Amount Raised:    $177,391.00
    Fundraising Status:    EC
    Filing Type:    CF
    Exelixis, Inc.

    Exelixis, Inc.

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncol...

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) ...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.